MONTELOEDER SL

Their core work

Monteloeder is a Spanish nutraceutical ingredient company specializing in plant-based formulations that target metabolic syndrome and obesity. Their core work involves developing standardized herbal extracts — primarily from hibiscus sabdariffa and lemon verbena — that activate the AMPK enzyme pathway, a key metabolic regulator. They operate between food science and pharmaceutical nutrition, producing functional food ingredients with documented physiological mechanisms rather than generic "wellness" claims. Their commercial model is ingredients-focused: they develop and patent the active compounds, then supply them to food and supplement manufacturers.

What they specialise in

How they've shifted over time

Monteloeder's H2020 trajectory is a textbook SME Instrument progression: they validated the concept of natural anti-obesity food ingredients in 2015 (Phase 1 feasibility), then moved into full product development and market preparation by 2017-2020 (Phase 2). The keyword data reflects this maturation — early-phase projects carried no technical keywords, while the later phase reveals a fully articulated scientific framework: AMPK enzyme mechanisms, specific botanical species (hibiscus sabdariffa, lemon verbena), and commercial framing as nutraceutical ingredients. The shift is from "can this work?" to "here is the science and here is the product."

Monteloeder appears to be moving toward established ingredient supplier status — the Phase 2 investment and nutraceutical framing suggest they are building a B2B ingredient brand rather than pursuing further academic research grants.

How they like to work

Monteloeder consistently operates as a solo project leader under the SME Instrument scheme, which by design does not require consortium partners. They have no recorded consortium collaborations in H2020, meaning they control their IP and development roadmap independently. For organizations looking to partner with them, Monteloeder would most likely engage as a specialized ingredient supplier or technology licensor rather than as a research consortium partner.

Monteloeder has no recorded consortium partners in the H2020 data, consistent with the solo-applicant structure of the SME Instrument. Their network is not visible through EU project data and likely operates through commercial ingredient supply channels rather than research consortia.

What sets them apart

Monteloeder occupies a specific niche at the intersection of food science and metabolic medicine — they are not a broad "natural ingredients" supplier but a company with a defined biological mechanism (AMPK activation) and named botanical sources. Their successful progression through both phases of the SME Instrument signals that EU evaluators found their science credible and their commercialization plan viable. For consortium builders in the functional food or nutraceutical space, they bring both validated compounds and SME Instrument grant experience.

Highlights from their portfolio

• INNOPREFAT
  Phase 2 award of over €1M under the SME Instrument represents a highly competitive achievement and confirms the commercial maturity of their herbal extract formulation targeting metabolic syndrome via AMPK activation.
• INNOPREFAT
  The Phase 1 to Phase 2 progression of the same project is the intended SME Instrument success path — Monteloeder is one of relatively few SMEs to complete both phases on the same concept.